Price$6.70-1.05 (-13.55%)
2026-03-052026-06-08
News · 26 weeks24-80%
2025-12-142026-06-07
Mix2090d
- Insider8(40%)
- Other6(30%)
- SEC Filings5(25%)
- Earnings1(5%)
Latest news
25 items- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Convenes Annual General Meeting 2026Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its 2026 Annual General Meeting will take place on Monday June 29, 2026 at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 20252. Consultative vote on the Compensation Report for the business year 20253. Appropria
- SECSEC Form 20-F filed by Addex Therapeutics Ltd20-F - Addex Therapeutics Ltd. (0001574232) (Filer)
- SECSEC Form NT 20-F filed by Addex Therapeutics LtdNT 20-F - Addex Therapeutics Ltd. (0001574232) (Filer)
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Reports Full Year 2025 Financial Results and Provides Corporate UpdateGABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease modelsContinued to reposition dipraglurant mGlu5 NAM for brain injury recoveryEntered option and collaboration agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryRegained rights to phase 2 mGlu2 PAM asset, ADX71149Partner, Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studiesStrategic investment in Stalicla SA, confirming commitment to advancing innovative treatments for neurological disordersCash position of CHF 1.6 million at December 31, 2025
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough ModelAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model. "Chronic cough remains a significant unmet medical need, particularly in patients suffering from idiopathic pulmonary fibrosis (IPF), where persistent coughing substantially impacts quality of li
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, is on track to complete its Phase 1 clinical study evaluating NTX-253 in Q2 2026. NTX-253 is an investigational potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The study is designed to generate a robust early-stage clinical data package assessing safety, tolerability, a
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough ModelAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model. "These important data in non-human primates together with previously reported guinea pig data demonstrates the therapeutic potential of our highly selective, orally available GABAB PAM," said Tim Dyer, CEO of Addex. "Chronic cough is a
- INSIDERSEC Form 3 filed by new insider Mills Roger3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lawton Vincent Michael3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERSEC Form 3 filed by new insider Teyssedou Lenaic Nathanael3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kalinichev Mikhail3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hill Raymond George3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dyer Timothy Mark3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERSEC Form 3 filed by new insider Nunn Jason Raleigh3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERSEC Form 3 filed by new insider Manke Isaac3 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder TreatmentData published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today publication of data in Molecular Psychiatry1 demonstrating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators (NAM) could be transformative in the treatment of anxiety and fear-related disorders, such as post-traumatic stress disorder (PTSD). In the study, scientists from the Center for Psychiatric Neurosciences (CNP, CHUV/UNIL)
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for SchizophreniaAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253. NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NTX-253 in healthy volunteers. "The progression
- PRAddex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC ("H.C. Wainwright & Co.") initially entered into on January 30, 2024. The at-the-market offering program enables Addex to offer and sell, from time to time at its sole discretion, ADSs having an aggregate offering price of up to $3.3 million through H.C. Wainwright & Co., as its sales agent. T
ADXN FAQ
6 questionsWhat does Addex Therapeutics Ltd do?
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals...Where does ADXN stock trade?
Addex Therapeutics Ltd (ADXN) is listed on NASDAQ.What sector and industry is ADXN in?
Addex Therapeutics Ltd operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ADXN?
Addex Therapeutics Ltd has had 2 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $3000.00 price target on 2024-07-31. Recent price targets range from $2100.00 to $3000.00.What companies are similar to ADXN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ADXN side-by-side with any of them on Quantisnow.How can I track ADXN on Quantisnow?
Quantisnow aggregates Addex Therapeutics Ltd's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADXN to receive live email and push alerts on every new disclosure.